Experimental drug [177Lu]Lu-PentixaTher: Injection of \[177Lu\]Lu-PentixaTher
Study summary
CXCR4 inhibition may represent a new therapeutic strategy in acute leukemia (AL) patients, not only by increasing chemosensitivity but also by preventing relapse of the disease by disruption of the interaction of residual leukemic cells with the bone marrow niche. Radiolabeled CXCR4 ligands have been developed for PET imaging (68Ga-PentixaFor; INN: Gallium (68Ga) boclatixafortide) and radioligand therapy (RLT) (\[177Lu\]Lu-PentixaTher/\[90Y\]Y-PentixaTher). \[177Lu\]Lu and \[90Y\]Y-PentixaTher have been tested in three multiple myeloma patients in named-patient use with a remarkable efficacy in 2 patients (Herrmann, 2016). Moreover, feasibility of CXCR4 PET imaging in AML was reported, providing a framework for future theranostic approaches targeting the CXCR4/CXCL12-defined leukemia-initiating cell niche (Herhaus, 2016).
Here a Phase I/II study to determine maximal tolerated dose (MTD) of a RLT using \[177Lu\]Lu-PentixaTher in relapsed/refractory AL was designed. This will be a standard phase I/II 3+3 dose escalation study. Five dose levels will be tested, so 6 to 21 patients have to be included in the study.
Eligibility
Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* AML/ALL (OMS) with \>5% of blasts in bone marrow (with or without extramedullary localisation)
* CXCR4+ (ratio \>2/isotypic control) at the time of pre-inclusion
* All previously treated AML/ALL patients who have experienced relapse or treatment failure with no alternative treatment
* At least 15 days since previous treatment
* Eastern Cooperative Oncology Group (ECOG) performance status \< 2
* eGFR ≥ 50 ml/min by MDRD or CKDEPI
* ASAT or ALAT \> 5 upper normal value (except in case of documented presence of leukemia in the liver)
* Serum bilirubin ≤ 30 µmol/l
* Negative pregnancy test documented prior to enrolment (for females of childbearing potential)
* Agree to use an effective form of contraception with sexual partners throughout study participation (for female and male patients who are fertile)
* No active cardiac dysfunction (LVEF \> 45%)
* DLCO \>40%
* Written informed consent
* Be willing and able to comply with scheduled visits and study procedures
* Affiliation with French social security system or beneficiary from such system
Exclusion Criteria:
* Meningeal involvement
* HIV positive
* Active Hepatitis B or C
* Active infection within 7 days of starting treatment
* Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 1 year
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
* Participation at the same time in another study in which investigational drugs are used
* Patient with contra-indications to Rhu-EPO, Rhu-GCSF, allopurinol, rasburicase, anti-histamines and corticosteroids
* Absence of written informed consent
* Pregnant or child breast feeding woman
* Patient under guardianship or trusteeship
* Patient under judicial protection
Primary outcome measure(s)
Safety of RLT using one injection of [177Lu]Lu-PentixaTher — Between Week 4 and Week 6 Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Tolerance — Between Week 4 and Week 6 Tolerance of the RLT will be evaluated by dosimetry studies, especially in terms of renal and hepatic doses delivered
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
